Loading patent…
AssigneeUniversity of Notre Dame
InventorsSteven Buechler, Amanda B. Hummon
Estimating the term…
Genetic biomarkers for left side colon cancer (LCC) (such as expression levels of an RNA transcript or expression product of NOX4, MMP3, or a combination) and right side colon cancer (RCC) (such as expression levels of an RNA transcript or expression product of CDCX2, FAM69A, or a combination), are disclosed. Methods for using the biomarkers in providing a prognosis of relapse-free survival probability in patients having LCC or RCC are also presented. Prognostic panels using gene expression values of the biomarkers are also presented. Computer implemented methods employing the biomarkers, and as well as for determining relapse-free survival probability in a patient having RCC or LCC are provided. A genetic method for classifying a colon cancer tissue as a RCC or as a LCC is also disclosed.
A panel of probes for indicating a 5-year right-side colon cancer (RCC) relapse probability of RCC in a post-surgery human RCC patient, said panel of probes consisting of detectably labeled single-stranded polynucleotides complementary to mRNA or cDNA of two or more genes selected from the group consisting of:
A panel of probes for indicating a 5-year right-side colon cancer (RCC) relapse probability of RCC in a post-surgery human RCC patient, said panel of probes consisting of detectably labeled single-stranded polynucleotides complementary to mRNA or cDNA of two or more genes selected from the group consisting of:
A panel of probes for indicating a 5-year RCC relapse probability of RCC in a post-surgery human RCC patient, said panel of probes consisting of detectably labeled single-stranded polynucleotides complementary to mRNA or cDNA of CDX2 and FAM69A.
A panel of probes for indicating a 5-year right-side colon cancer (RCC) relapse probability of RCC in a post-surgery human RCC patient, said panel of probes consisting of detectably labeled single-stranded polynucleotides complementary to mRNA or cDNA of two or more genes selected from the group consisting of:
A diagnostic screening tool for indicating a 5-year right-side colon cancer (RCC) relapse probability of RCC in a post-surgery human RCC patient, said diagnostic screening tool comprising a panel of probes consisting of detectably labeled single-stranded polynucleotides complementary to mRNA or cDNA of two or more genes selected from the group consisting of:
Dependencies are inferred from the claim text.